Science Explorer Back to mapMap
Discussion
Institution · Develco Pharma (Switzerland)

Most cited papers from Develco Pharma (Switzerland)

Develco Pharma (Switzerland)

What are the most cited papers from Develco Pharma (Switzerland)?

The most cited paper from Develco Pharma (Switzerland) is "Avosentan for Overt Diabetic Nephropathy" (Johannes F.E. Mann, Damian Green, Kenneth Jamerson et al., 2010), with 493 citations. Next come "Extended‐release but not immediate‐release and subcutaneous methylnaltrexone antagonizes the loperamide‐induced delay of whole‐gut transit time in healthy subjects" (19) and "Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects" (13).

Showing 17 of 17 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Avosentan for Overt Diabetic Nephropathy Johannes F.E. Mann, Damian Green, Kenneth Jamerson et al. · Journal of the American Society of Nephrology Open access 18 Feb 2010 493
2 Extended‐release but not immediate‐release and subcutaneous methylnaltrexone antagonizes the loperamide‐induced delay of whole‐gut transit time in healthy subjects Julia Kolbow, Christiane Modeß, Danilo Wegner et al. · The Journal of Clinical Pharmacology 27 Aug 2015 19
3 Chiral Pharmacokinetics and Metabolite Profile of Prolonged-release Ketamine Tablets in Healthy Human Subjects Mahmoud Hasan, Christiane Modeß, Tarek Roustom et al. · Anesthesiology 21 May 2021 13
4 Clinical evaluation of the first oxycodone once daily prolonged release tablet in moderate to severe chronic pain: a randomized, double-blind, multicenter, cross-over, non-inferiority study to investigate efficacy and safety in comparison with an established oxycodone twice daily prolonged release tablet Eberhard Albert Lux, Marcin Janecki, Martina Alice Maritz · Current Medical Research and Opinion Open access 22 Jul 2014 9
5 Once‐Daily Oxycodone Prolonged‐Release Tablets Are Resistant to Alcohol‐Induced Dose Dumping: Results From a Randomized Trial in Healthy Volunteers Nils Burger, Douglas Fraser, Martina Alice Maritz et al. · Clinical and Translational Science Open access 6 Feb 2020 8
6 Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet Bernhard Scheidel, Martina Alice Maritz, Yves J. Gschwind et al. · International Journal of Clinical Pharmacology and Therapeutics Open access 21 Sep 2017 8
7 Oral Prolonged-Release Ketamine for Treatment-Resistant Depression Martin Walter, Christine zu Eulenburg, Ani Damyanova et al. · JAMA Network Open Open access 24 Jun 2026 2
8 [P1–051]: RESULTS FROM A 3‐MONTH STUDY IN HEALTHY SUBJECTS AGED 60 YEARS WITH THE BACE INHIBITOR CNP520 Mike Ufer, Marie‐Laure Rouzade‐Dominguez, Gunilla Huledal et al. · Alzheimer s & Dementia Open access Jul 2017 1
9 Pharmacokinetics of a New Biphasic Release Methylphenidate Preparation (Methysym®) Sven Ulrich, Britta Langer, Hélène Rey et al. · Psychopharmakotherapie Open access 2025 0
10 Placebo level dissociation in treatment resistant depression treated with oral prolonged release ketamine – an exploratory analysis of two trials L. Arvastson, E. Papanastasiou, K. Schmid et al. · Neuroscience Applied Open access 2026 0
11 Antidepressant effect of ketamine unrelated to dissociation: Results from an exploratory mediation analysis of the KET01-02 study Lars Arvastson, E. Papanastasiou, Kendra K. Schmid et al. · European Psychiatry Open access Apr 2025 0
12 Acute tolerability of antidepressant dose of oral prolonged-release ketamine (KET01) in patients with treatment-resistant depression and healthy volunteers A. Damyanova, Kendra K. Schmid, E. Papanastasiou et al. · Neuroscience Applied Open access 2024 0
13 Sleep quality and daytime sleepiness/sedation during treatment with oral prolonged-release KET01 ketamine: combined results of the KET01-02 and KET01-03 trials E. Papanastasiou, Christine zu Eulenburg, A. Damyanova et al. · Neuroscience Applied Open access 2024 0
14 Rapid reduction of depressive symptoms with minimal dissociation: results from the KET01-02 and KET01-03 trials with oral prolonged-release (PR) ketamine KET01 Christine zu Eulenburg, E. Papanastasiou, Kendra K. Schmid et al. · European Psychiatry Open access Apr 2024 0
15 Production Operations Forum J. J. Kleckner, R.C. Dickerson, P.M. Snider et al. Conference paper Oct 1986 0
16 Dose-Dependent Pharmacokinetics and Metabolisms of Prolonged-Release Ketamine Tablets in Healthy Subjects Mahmoud Hasan, Christiane Modeß, Tarek Roustom et al. · Clinical Therapeutics Open access 21 Jun 2017 0
17 Efficacy of a new once daily hydromorphone formulation in comparison with twice daily administration in chronic pain: a randomized, double-blind, cross-over study Gudrun Nold, Martina Alice Maritz, Andreas Schwittay et al. · Current Medical Research and Opinion 29 Jan 2016 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.